TN2009000163A1 - Compounds and compositions as protein kinase inibitors - Google Patents

Compounds and compositions as protein kinase inibitors

Info

Publication number: TN2009000163A1
Authority: TN; Tunisia
Prior art keywords: compounds; compositions; inibitors; protein kinase; disorders
Prior art date: 2006-11-03

Application number

TNP2009000163A

Other languages

English (en)

Inventor

Donatella Chianelli

Xiaolin Li

Xiaodong Liu

Jon Loren

Valentina Molteni

Juliet Nabakka

Laszlo Revesz

Lawrence B Perez

Clinton Brooks

Wojciech Wrona

Paul W Manley

Breiteinstei

Original Assignee

Norvartis Ag

Irm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-03

Filing date

2009-04-29

Publication date

2010-10-18

2009-04-29 Application filed by Norvartis Ag, Irm Llc filed Critical Norvartis Ag

2010-10-18 Publication of TN2009000163A1 publication Critical patent/TN2009000163A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Tropical Medicine & Parasitology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Child & Adolescent Psychology (AREA)
Ophthalmology & Optometry (AREA)

TNP2009000163A 2006-11-03 2009-04-29 Compounds and compositions as protein kinase inibitors TN2009000163A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US86437806P	2006-11-03	2006-11-03
PCT/US2007/083543 WO2008058037A1 (fr)	2006-11-03	2007-11-02	Composés et compositions en tant qu'inhibiteurs des protéines kinases

Publications (1)

Publication Number	Publication Date
TN2009000163A1 true TN2009000163A1 (en)	2010-10-18

Family

ID=39119736

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000163A TN2009000163A1 (en)	2006-11-03	2009-04-29	Compounds and compositions as protein kinase inibitors

Country Status (20)

Country	Link
US (1)	US20100048539A1 (fr)
EP (1)	EP2079729A1 (fr)
JP (1)	JP2010509349A (fr)
KR (2)	KR20120049397A (fr)
CN (1)	CN101622244A (fr)
AU (1)	AU2007317349B2 (fr)
BR (1)	BRPI0718677A2 (fr)
CA (1)	CA2668190A1 (fr)
CO (1)	CO6241115A2 (fr)
CR (1)	CR10755A (fr)
EA (1)	EA200970447A1 (fr)
EC (1)	ECSP099378A (fr)
IL (1)	IL198315A0 (fr)
MA (1)	MA30906B1 (fr)
MX (1)	MX2009004716A (fr)
NO (1)	NO20092138L (fr)
RU (1)	RU2009120882A (fr)
SM (1)	SMAP200900031A (fr)
TN (1)	TN2009000163A1 (fr)
WO (1)	WO2008058037A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2390227T3 (es)	2004-09-09	2012-11-07	Natco Pharma Limited	Nuevos derivados de fenilaminopirimidina como inhibidores de la BCR-ABL kinasa
US8735415B2 (en)	2004-09-09	2014-05-27	Natco Pharma Limited	Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
LT2799427T (lt)	2006-07-05	2018-11-26	Fibrotech Therapeutics Pty Ltd	Terapiniai junginiai
EA019524B1 (ru) *	2007-05-04	2014-04-30	Айрм Ллк	СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ с-kit И PDGFR
EP2152079A4 (fr) *	2007-06-04	2011-03-09	Avila Therapeutics Inc	Composés hétérocycliques et utilisations de ceux-ci
JP5303557B2 (ja)	2007-08-22	2013-10-02	アイアールエム・リミテッド・ライアビリティ・カンパニー	キナーゼ阻害剤である２−ヘテロアリールアミノ−ピリミジン誘導体
WO2009026276A1 (fr)	2007-08-22	2009-02-26	Irm Llc	Composés et compositions de 5- (4- (haloalkoxy) phényl) pyrimidine-2-amine utilisés comme inhibiteurs de kinases
US20110190313A1 (en) *	2008-08-13	2011-08-04	Steve Pascoe	Treatment of Pulmonary Arterial Hypertension
UA103918C2 (en)	2009-03-02	2013-12-10	Айерем Элелси	N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
RU2011140404A (ru) *	2009-03-06	2013-04-20	Новартис Аг	Применение производных пиримидиламинобензамида для лечения нарушений, опосредованных киназой, содержащей мотив лейциновой "молнии" и стерильный альфа мотив (zak)
US9062076B2 (en) *	2009-10-22	2015-06-23	Fibrotech Therapeutics Pty Ltd	Fused ring analogues of anti-fibrotic agents
KR101954044B1 (ko) *	2010-05-07	2019-03-04	질레드 코네티컷 인코포레이티드	피리돈 및 아자-피리돈 화합물 및 사용 방법
EP2576532B1 (fr)	2010-06-07	2018-07-18	Novomedix, LLC	Composés furanyliques et leur utilisation
EP2640702A1 (fr) *	2010-11-17	2013-09-25	Novartis AG	Composés 3-(aminoaryl)-pyridine
WO2013022766A1 (fr)	2011-08-05	2013-02-14	Flynn Gary A	Préparation et procédés d'utilisation d'ortho-aryle hétéroaryle à 5 chaînons -carboxamide contenant des inhibiteurs de kinases multicibles
CN103797011B (zh)	2011-09-01	2016-03-30	诺华股份有限公司	作为c-Kit激酶抑制剂的化合物和组合物
US9199981B2 (en)	2011-09-01	2015-12-01	Novartis Ag	Compounds and compositions as C-kit kinase inhibitors
UY34305A (es)	2011-09-01	2013-04-30	Novartis Ag	Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
BR112014004319A2 (pt) *	2011-09-01	2017-03-14	Irm Llc	compostos e composições como inibidores de c-kit cinase
US9073921B2 (en)	2013-03-01	2015-07-07	Novartis Ag	Salt forms of bicyclic heterocyclic derivatives
WO2014170350A1 (fr) *	2013-04-17	2014-10-23	Albert Ludwigs Universität Freiburg	Composés destinés à être utilisés comme inhibiteurs de bromodomaine
CN103288804A (zh) *	2013-05-24	2013-09-11	苏州明锐医药科技有限公司	一种尼洛替尼的制备方法
CN105283443B (zh)	2013-06-05	2018-08-17	株式会社C&C新药研究所	杂环衍生物及其用途
WO2015085229A1 (fr) *	2013-12-08	2015-06-11	Van Andel Research Institute	Inhibiteurs d'autophagie
HRP20221373T1 (hr)	2014-03-07	2023-01-06	Biocryst Pharmaceuticals, Inc.	Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi
CN111170998B (zh) *	2014-11-05	2023-04-11	益方生物科技(上海)股份有限公司	嘧啶或吡啶类化合物、其制备方法和医药用途
CN106187995A (zh) *	2015-05-05	2016-12-07	天津国际生物医药联合研究院	含酰胺键杂环类化合物及其制备方法和应用
EP3344600B1 (fr) *	2015-09-04	2021-02-24	Dow Agrosciences LLC	Molécules présentant une utilité en tant que pesticide, et leurs intermédiaires, compositions et procédés
CN108513537A (zh) *	2015-09-23	2018-09-07	米纳瓦生物技术公司	筛选分化干细胞的试剂的方法
ES2949357T3 (es) *	2016-03-09	2023-09-28	Raze Therapeutics Inc	Inhibidores de 3-fosfoglicerato deshidrogenasa y usos de los mismos
SI3426243T1 (sl)	2016-03-09	2021-11-30	Raze Therapeutics, Inc.	Zaviralci 3-fosfoglicerat dehidrogenaze in uporabe le-teh
CN105974131B (zh) *	2016-06-16	2017-12-26	武汉大学	c‑Kit作为药物成瘾治疗靶点的应用
MX392368B (es)	2016-12-15	2025-03-24	Univ California	Composiciones y metodos para el tratamiento del cancer
SG11201907139UA (en)	2017-02-03	2019-09-27	Certa Therapeutics Pty Ltd	Anti-fibrotic compounds
JP6994715B2 (ja) *	2017-10-04	2022-02-04	国立大学法人京都大学	Ｂｃｒ－Ａｂｌタンパク質イメージング用分子プローブ
CN108187052B (zh) *	2018-02-05	2021-06-08	苏州大学	Akt抑制剂在制备治疗血小板数量减少相关疾病药物中的用途
US11767319B2 (en)	2020-07-15	2023-09-26	Third Harmonic Bio, Inc.	Crystalline forms of a selective c-kit kinase inhibitor
JP7511294B2 (ja) *	2020-08-11	2024-07-05	ホーナンメディノファーマシューティカルテクノロジーカンパニーリミテッド	Ｆｇｆｒ阻害剤化合物及びその使用
US11629143B2 (en)	2020-10-01	2023-04-18	Vibliome Therapeutics, Llc	HipK4 inhibitors and uses thereof
US11744823B2 (en)	2020-11-19	2023-09-05	Third Harmonic Bio, Inc.	Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
CN113797345B (zh) *	2021-10-22	2023-05-16	北京大学人民医院	糖皮质激素与糖酵解调节剂在制备急性移植物抗宿主病的药物中的应用
CA3250517A1 (fr) *	2022-04-27	2023-11-02	Mrja Therapeutics, Inc.	Entités chimiques, compositions et procédés
EP4630423A1 (fr) *	2022-12-07	2025-10-15	Third Harmonic Bio, Inc.	Composés et compositions utilisés en tant qu'inhibiteurs de c-kit kinase
US20250034138A1 (en) *	2023-07-14	2025-01-30	Enanta Pharmaceuticals, Inc.	Compounds and Compositions as C-Kit Kinase Inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE331519T1 (de) *	2001-05-16	2006-07-15	Gpc Biotech Ag	Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
GB0215676D0 (en) *	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
GB0222514D0 (en) *	2002-09-27	2002-11-06	Novartis Ag	Organic compounds
ES2390227T3 (es) *	2004-09-09	2012-11-07	Natco Pharma Limited	Nuevos derivados de fenilaminopirimidina como inhibidores de la BCR-ABL kinasa
AU2005321946B2 (en) *	2004-12-23	2012-08-16	Deciphera Pharmaceuticals, Llc	Enzyme modulators and treatments
EP1836173A4 (fr) *	2004-12-23	2009-07-08	Deciphera Pharmaceuticals Llc	Medicaments anti-inflammatoires
KR100674813B1 (ko) *	2005-08-05	2007-01-29	일양약품주식회사	Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법

2007
- 2007-11-02 BR BRPI0718677-0A patent/BRPI0718677A2/pt not_active IP Right Cessation
- 2007-11-02 AU AU2007317349A patent/AU2007317349B2/en not_active Expired - Fee Related
- 2007-11-02 WO PCT/US2007/083543 patent/WO2008058037A1/fr not_active Ceased
- 2007-11-02 US US12/513,498 patent/US20100048539A1/en not_active Abandoned
- 2007-11-02 EP EP07844851A patent/EP2079729A1/fr not_active Withdrawn
- 2007-11-02 CA CA002668190A patent/CA2668190A1/fr not_active Abandoned
- 2007-11-02 CN CN200780049160A patent/CN101622244A/zh active Pending
- 2007-11-02 EA EA200970447A patent/EA200970447A1/ru unknown
- 2007-11-02 KR KR1020127008731A patent/KR20120049397A/ko not_active Withdrawn
- 2007-11-02 JP JP2009536405A patent/JP2010509349A/ja not_active Ceased
- 2007-11-02 RU RU2009120882/04A patent/RU2009120882A/ru not_active Application Discontinuation
- 2007-11-02 KR KR1020097011383A patent/KR20090075889A/ko not_active Ceased
- 2007-11-02 MX MX2009004716A patent/MX2009004716A/es not_active Application Discontinuation
2009
- 2009-04-23 IL IL198315A patent/IL198315A0/en unknown
- 2009-04-29 CR CR10755A patent/CR10755A/es not_active Application Discontinuation
- 2009-04-29 TN TNP2009000163A patent/TN2009000163A1/fr unknown
- 2009-05-04 CO CO09044589A patent/CO6241115A2/es not_active Application Discontinuation
- 2009-05-04 SM SM200900031T patent/SMAP200900031A/it unknown
- 2009-05-18 MA MA31895A patent/MA30906B1/fr unknown
- 2009-06-02 NO NO20092138A patent/NO20092138L/no not_active Application Discontinuation
- 2009-06-02 EC EC2009009378A patent/ECSP099378A/es unknown

Also Published As

Publication number	Publication date
NO20092138L (no)	2009-07-13
BRPI0718677A2 (pt)	2013-11-26
EP2079729A1 (fr)	2009-07-22
MA30906B1 (fr)	2009-11-02
JP2010509349A (ja)	2010-03-25
AU2007317349B2 (en)	2011-10-20
KR20090075889A (ko)	2009-07-09
ECSP099378A (es)	2009-07-31
RU2009120882A (ru)	2010-12-10
KR20120049397A (ko)	2012-05-16
IL198315A0 (en)	2010-02-17
CR10755A (es)	2009-06-04
CA2668190A1 (fr)	2008-05-15
MX2009004716A (es)	2009-07-17
EA200970447A1 (ru)	2009-10-30
CO6241115A2 (es)	2011-01-20
WO2008058037A1 (fr)	2008-05-15
SMAP200900031A (it)	2009-07-14
CN101622244A (zh)	2010-01-06
AU2007317349A1 (en)	2008-05-15
US20100048539A1 (en)	2010-02-25

Publication	Publication Date	Title
TN2009000163A1 (en)	2010-10-18	Compounds and compositions as protein kinase inibitors
MX2009011951A (es)	2009-12-11	Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2010009207A (es)	2011-03-03	Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
MX2009011950A (es)	2009-12-11	Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
TN2012000081A1 (en)	2013-09-19	Compounds and compositions as protein kinase inhibitors
WO2009097287A9 (fr)	2009-10-01	Composés et compositions comme inhibiteurs de kinases
MX2009011952A (es)	2009-12-11	Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
EA200900983A1 (ru)	2010-02-26	Соединения и композиции в качестве ингибиторов киназы
MXPA05010711A (es)	2005-12-15	Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
TN2013000348A1 (en)	2015-01-20	Compounds and compositions as trk inhibitors
TN2014000068A1 (en)	2015-07-01	Compounds and compositions as c-kit kinase inhibitors
TN2014000061A1 (en)	2015-07-01	COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
MX2009006170A (es)	2009-06-19	Compuestos y composiciones como inhibidores de cinasa.
EA201190158A1 (ru)	2012-04-30	Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
BR112014004465A2 (pt)	2017-03-28	compostos e composições como inibidores de pdgfr cinase
TN2009000128A1 (en)	2010-10-18	Dihydropyridine derivatives useful as protein kinase inhibitors
BRPI0814065B8 (pt)	2021-05-25	derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
WO2011014795A3 (fr)	2011-06-03	Composés et compositions pouvant servir d'inhibiteurs de la kinase syk
MX2009000333A (es)	2009-03-13	Pirrilopirimidinas para composiciones farmaceuticas.
UA103617C2 (ru)	2013-11-11	Производные тиенопиридона как активаторы амр-активированной протеинкиназы (амрк)
BR112014004319A2 (pt)	2017-03-14	compostos e composições como inibidores de c-kit cinase
WO2008011611A3 (fr)	2008-05-02	Composés et compositions utilisés en tant qu'inhibiteurs de l'itpkb
MX2010010877A (es)	2010-10-26	Compuestos y composiciones como inhibidores de itpkb.
TW200639155A (en)	2006-11-16	Thiazolidinones, their production and use as pharmaceutical agents
EA200901656A1 (ru)	2010-06-30	СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ ITPKb